logo.gif
Auris Medical Announces Launch of New Corporate Website
July 16, 2021 09:00 ET | Auris Medical AG
Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
logo.gif
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
June 28, 2021 08:30 ET | Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
AAFA and Healthy Air Partners Coalition Meet with EPA on Pollution and Climate Change
May 20, 2021 15:25 ET | Asthma and Allergy Foundation of America
Washington, D.C, May 20, 2021 (GLOBE NEWSWIRE) -- Today the Asthma and Allergy Foundation of America (AAFA) joined 17 other health and medical organizations in a meeting with U.S. Environmental...
logo.gif
Auris Medical Provides Update on Bentrio Program in Allergy
May 07, 2021 09:05 ET | Auris Medical AG
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...
Zoom-In on Health Equity: AAFA Asks Congress to Tackle Racial Disparities in Asthma and Allergy
April 30, 2021 14:22 ET | Asthma and Allergy Foundation of America
Washington, D.C, April 30, 2021 (GLOBE NEWSWIRE) -- Each year, the Asthma and Allergy Foundation of America (AAFA) brings patient spokespeople and advocates from across the nation to Congress to...
AAFA Meets Asthma and Allergy Awareness Month with 31 DAYS OF ACTION
April 29, 2021 14:03 ET | Asthma and Allergy Foundation of America
Washington, D.C, April 29, 2021 (GLOBE NEWSWIRE) -- May is National Asthma and Allergy Awareness Month. This year the Asthma and Allergy Foundation of America (AAFA) is encouraging everyone to look...
logo.gif
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
April 13, 2021 07:45 ET | Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Chief Operating Officer
March 25, 2021 09:10 ET | Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
March 12, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
Miravo Healthcare to present at the Q1 Virtual Investor Summit
March 11, 2021 07:35 ET | Nuvo Pharmaceuticals Inc.
MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare™ today announced that Jesse Ledger, President...